Debiopharm on the problems in the antibiotics market

This content was published on October 15, 2020 - 11:00

Debiopharm executives talk about the challenges of developing antibiotics and why it helps to be a family-owned company without the pressure of shareholders.

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Share this story